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Cajal bodyThe dysfunction of the ubiquitin proteasome system has been related to a broad array of neurodegenerative dis-
orders in which the accumulation of misfolded protein aggregates causes proteotoxicity. The ability of protea-
some inhibitors to induce cell cycle arrest and apoptosis has emerged as a powerful strategy for cancer
therapy. Bortezomib is a proteasome inhibitor used as an antineoplastic drug, although its neurotoxicity fre-
quently causes a severe sensory peripheral neuropathy. In this study we used a rat model of bortezomib treat-
ment to study the nucleolar and Cajal body responses to the proteasome inhibition in sensory ganglion
neurons that are major targets of bortezomib-induced neurotoxicity. Treatment with bortezomib induced
dose-dependent dissociation of protein synthesis machinery (chromatolysis) and nuclear retention of poly(A)
RNA granules resulting in neuronal dysfunction. However, as a compensatory response to the proteotoxic stress,
both nucleoli and Cajal bodies exhibited reactive changes. These include an increase in the number and size of
nucleoli, strong nucleolar incorporation of the RNA precursor 5′-ﬂuorouridine, and increased expression of
both 45S rRNA and genes encoding nucleolar proteins UBF, ﬁbrillarin and B23. Taken together, these ﬁndings ap-
pear to reﬂect the activation of the nucleolar transcription in response to proteotoxic stress Furthermore, the
number of Cajal bodies, a parameter related to transcriptional activity, increases upon proteasome inhibition.
We propose that nucleoli and Cajal bodies are important targets in the signaling pathways that are activated
by the proteotoxic stress response to proteasome inhibition. The coordinating activity of these two organelles
in the production of snRNA, snoRNA and rRNAmay contribute to neuronal survival after proteasome inhibition.
This article is part of a Special Issue entitled: Role of the Nucleolus in Human Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The ubiquitin-dependent proteasome system (UPS) is the major
pathway responsible for cellular protein degradation in eukaryotic
cells. Proteasomes degrade essential proteins for cellular homeostasis in-
cluding those involved in transcription, DNA repair, cell cycle progres-
sion and apoptosis [1,2]. Proteolysis is performed by the 26S
proteasome, a multi-subunit complex formed by the 20S proteolytic
core and one or two ﬂanking 19S regulatory particles that recog-
nize polyubiquitinated protein substrates [3,2]. In the cell nucleus,
proteasomes are abundant in euchromatin domains, nuclear speckles
of pre-mRNA splicing factors, PML (promyelocytic leukemia) nuclear
bodies and clastosomes [4,5]. Proteasomal activity has been detected
with ﬂuorogenic protein substrates in nucleoplasmic foci, but not
in the nucleolus [6,7]. Nuclear proteolysis seems to be involved in
quality-control mechanisms and in the turnover of short-lived proteins,e Nucleolus in Human Disease.
y and Cell Biology, Faculty of
tander, Spain. Tel.: +34 942
ights reserved.particularly certain transcription regulators and splicing factors [4,5]. In
the nervous system, dysfunction of proteasome is an age-related process
and also occurs in several neurodegenerative diseases [8].
The ability of proteasome inhibitors such as bortezomib to in-
duce cell death has emerged as a powerful strategy for cancer therapy
[9]. Bortezomib is a reversible inhibitor that primarily targets the
chymotrypsin-like activity of the proteasome β5-subunit and to a
somewhat lesser extent the caspase-like activity of the β1 proteasome
subunit [3]. Bortezomib cytotoxicity in cancer cells is mediated by sev-
eral mechanisms, including inhibition of NF-kB, up-regulation of
genes involved in pro-apoptotic pathways and induction of endoplas-
mic reticulum stress [10]. However, peripheral neurotoxicity is the
most relevant dose-limiting side effect of bortezomib treatment, and
frequently leads to a severe sensory peripheral neuropathy [11,12].
The nucleolus is the nuclear factory for rRNA synthesis, processing
of the maturing rRNA transcripts and preribosome subunit assem-
bly. These processes are reﬂected in the structural organization of the
main nucleolar components, ﬁbrillar centers (FCs), dense ﬁbrillar com-
ponent (DFC) and granular component (GC) [13–16]. In addition, several
studies support that the nucleolus is a central hub for sensing and coor-
dinating cellular stress response [17,18]. Furthermore, recent studies in-
dicate a functional link between the nucleolus and the UPS, suggesting
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ments with proteasome inhibitors can alter the nucleolar morphology
and function [20–22].
Mammalian projection neurons exhibit prominent nucleoli with a
high rate of ribosome biogenesis for the maintenance of active protein
synthesis and cellular proteostasis. Neurons accommodate, at least in
part, changes in the demand for protein synthesis by regulating the num-
ber and size of nucleoli, aswell as the number of ﬁbrillar centers [23–26].
In this way, a recent study has shown that the postsynaptic density pro-
tein AIDA-1 mediates a link between synaptic activity and protein syn-
thesis by regulating neuronal nucleologenesis [27]. Moreover, nucleolar
activity may inﬂuence the potential for neurorepair and nerve regenera-
tion [25,28]. Conversely, morphological and biochemical manifestations
of nucleolar dysfunction are associated with certain neurological disor-
ders [29,28,30,31].
Cajal bodies (CBs) are nuclear structures discovered by Cajal in
mammalian neurons [32]. They concentrate many molecular com-
ponents, including coilin, the survival motor neuron (SMN) pro-
tein, the nucleolar protein ﬁbrillarin and small nuclear (snRNPs) and
nucleolar ribonucleoproteins (snoRNPs) required for pre-mRNA and
pre-rRNA processing [33–36]. In neurons, CB number positively corre-
lates with neuronal activity [24,37]. Moreover, an activity-dependent
association of CBs with nucleoli has been reported in several neuronal
populations [38,27].
In rat andmousemodels of bortezomib treatment,we andothers have
reported that sensory ganglion neurons are primary targets of the periph-
eral neurotoxicity when using doses equivalent to those used in clinical
patients [39,40]. In particular, we demonstrated that the bortezomib-
induced inhibition of proteasome activity, measured by cleavage of a
ﬂuorogenic substrate, caused a proteotoxic stress characterized by the ac-
cumulation of ubiquitylated proteins, dissolution of the rough endoplas-
mic reticulum (chromatolysis) and nuclear retention of polyadenylated
RNAs in nuclear bodies called poly(A) granules [39]. Here we have ana-
lyzed the effects of the bortezomib-induced proteasome inhibition on
the structure, organization and function of the nucleoli, as well as on the
organization of CBs, in rat sensory ganglion neurons. We show that
proteasome inhibition induces dose-dependent nucleolar hypertrophy
and nucleologenesis, activates rRNA synthesis, and increases the number
of CBs. This nucleolar response supports the participation of the nucleolus
in a compensatory response to the proteotoxic stress inducedproteasome
inhibition, which may be important for neuronal survival.
2. Material and methods
2.1. Rats
Experiments were designed and performed to minimize the use of
animals using a total of 60 young male Sprague–Dawley young rats of
125–130 g, distributed into one control and two experimental groups
treated with low or high doses of bortezomib (n = 20 per group). Ani-
mal care and handling was in accordance with Spanish legislation
(Spanish Royal Decree 53/2013 BOE) and the guidelines of the
European Commission for the accommodation and care of laboratory
animals (revised in Appendix A of the Council Directive 2010/63/UE).
The experimental plan was preliminarily examined and approved by
the Ethics Committee of the University of Cantabria. All the animals
were housed in a limited access environment with a 12-h light/dark
cycle, where room temperature and relative humidity were set at
22 ± 2 °C and 55 ± 10% respectively and there was free access to
food andwater. Animal sacriﬁcewas performed under deep pentobarbi-
tal anesthesia (50 mg/kg).
2.2. Drug administration and sacriﬁce
For the study of the nuclear effects of proteasome inhibition, we
used the proteasome inhibitor bortezomib (Velcade, provided byMillennium Pharmaceuticals Inc., Cambridge, MA). The animals re-
ceived two doses of bortezomib 0.2 mg/kg (low doses, Btz-LD) or
0.5 mg/kg (high doses, Btz-HD), dissolved in sterile saline and adminis-
tered intravenously via the tail vein, on days 1 and 3 andwere sacriﬁced
1d post-administration of the second dose.Moreover, the administration
of twodoses (0.5 mg/kg twice aweek)waswell tolerated by the Sprague
Dawley rats and no animals died during the experiment. Saline-treated
rats were used as controls. At the end of the treatment period the rats
were sacriﬁced. The general condition of the animals was assessed daily.
2.3. Immunoﬂuorescence and confocal microscopy
For immunoﬂuorescence and in situ hybridization for poly(A) RNA
the animals were perfused under deep anesthesia with pentobarbital
(50 mg/kg) with 3.7% paraformaldehyde (freshly prepared) in PBS. As
a model of sensory ganglion neurons we used trigeminal ganglia. After
ﬁxation, the gangliawere removed andwashed in PBS. Tissue fragments
from trigeminal ganglia were transferred to a drop of PBS on a silicon-
ized slide and squash preparations of dissociated neurons were per-
formed following the procedure previously reported [38].
For immunoﬂuorescence, the sampleswere, then, sequentially treat-
ed with 0.5% Triton X-100 in PBS for 45 min, 0.1 M glycine in PBS con-
taining 1% bovine serum albumin (BSA) for 30 min and 0.05% Tween
20 in PBS for 5 min. The sampleswere incubated for 3 hwith the prima-
ry antibody containing 1% BSA at room temperature, washedwith 0.05%
Tween 20 in PBS, incubated for 45 min in the speciﬁc secondary anti-
body conjugated with FITC or TexasRed (Jackson, USA), washed in PBS
and mounted with the ProLong anti-fading medium (Invitrogen).
Confocal images were obtained with a LSM510 (Zeiss, Germany)
laser scanning microscope and using a 63× oil (1.4 NA) objective. In
order to avoid overlapping signals, images were obtained by sequential
excitation at 488 nm and 543 nm, to detect FITC and TexasRed, respec-
tively. Images were processed using Photoshop software.
The morphometric and quantitative analysis of the nucleolar size
and nucleoli and CB numbers per neuron were performed in the popu-
lation of large neurons (≥40 μm) [38]. Dissociated neurons were im-
munostained for B23 for nucleolar parameters, and coimmunolabeled
for coilin and SMN to estimate CB number. Nucleolar diameters (only
of mononucleolated neurons) and nucleoli and CB numbers were esti-
mated on confocal images using a 63× oil objective and the LSM510
software for morphometric and quantitative analysis. Data were ana-
lyzed using one-way ANOVA followed by Bonferroni tests for compari-
sons. Statistical signiﬁcance was set at p b 0.05. All the analyses were
carried out using GraphPad software for Windows.
2.4. Antibodies
The following primary antibodies were used in this study. Mouse
monoclonal antibodies anti-UBF (F-9) (Santa Cruz Lab. La Jolla, CA, USA,
dilution 1:100 IF), anti-SMN (BD transduction laboratories, dilution 1:50
IF), anti-ﬁbrillarin (Abcam, dilution 1:500 IF), anti-p53 (Pab 246) (Santa
Cruz Lab. La Jolla, CA, USA, dilution 1:500WB) and anti-B23 (Abcam, dilu-
tion 1:200 IF). Rabbit polyclonal antibodies anti-coilin (210.4) (dilution
1:200 IF), anti-ﬁbrillarin ([41], dilution 1:100, immunogold), anti-Pp53
(Ser15) (Cell Signaling, dilution 1:1000 WB) and anti-Myc (Santa Cruz
Lab. La Jolla, CA, USA, dilution 1:1000 WB). Goat polyclonal antibody
anti-actin (Santa Cruz Lab. La Jolla, CA, USA, dilution 1:2000 WB).
2.5. In situ hybridization for poly(A) RNAs
Sensory ganglion neurons ﬁxed and dissociated as previously de-
scribed were used for ﬂuorescence in situ hybridization. Preparations
of ganglion neurons were permeabilized with TBS-E-SDS for 15 min at
37 °C, washed three times in 6× SSPE-Tween 20 0.1% for 15 min, and
incubated with the probe containing tRNA for 3 h, at 42ªC in a hu-
midiﬁed chamber. An oligo dT (50)-mer, 5′-end labeled with biotin
Table 1
Information on the primers used for real-time quantitative PCR.
Name GenBank Forward primer 5′-3′ Reverse Primer 5′-3′
45S pre rRNA NM_001100771.1 tggggcagctttatgacaac tagcaccaaacgggaaaacc
18S rRNA – gttggttttcggaactgaggc gtcggcatcgtttatggtcg
Nucleophosmin NM_012992.4 catcttctgactctgcatcttcc ggtcttgaggttgaagtgtgg
Ubtf NM_001105723.2 gaagagaaggcagcttcagg cttctcggacaagtcgttcc
Fbl NM_001025643.1 attgactccacagcctcagc gcgtggtctcgttcataagg
Nucleolin NM_012749.2 tgctggagttgtggtagcc tgacagcagtggagaagagg
Coilin NM_017360.1 ccagcatgttcttggacacc agcctagcttcaccttcagc
p53/Tp53 NM_030989.3 accagcacaagctcctctcc ctctcggaacatctcgaagc
c-myc NM_012603.2 gaggtggaaaacccgacag cagcagctcgaatttcttcc
Rps14 NM_022672.1 tcactgccctgcatatcaaac tccttcgagtgctgtcagag
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to poly(A) RNA. The hybridization mixture contained 80 ng oligo dT
[50], 2xSSC, 1 mg/ml tRNA, 10% dextran sulfate and 25% formamide.
After hybridization, sensory ganglion neurons were washed in 6xSSC
for 15 min, and then washed in 4× SSC-Tween 20 0.1% for 15 min at
room temperature. The hybridization signal was detected with FITC-
avidin for 30 min. To amplify this signal, neuronal samples were incu-
bated with avidin–biotin for 30 min, washed in 4× SSC-Tween 20 0.1%
for 15 min and then incubated with FITC-avidin for 30 min. All samples
were mounted with the ProLong anti-fading medium (Invitrogen).
2.6. Run-on transcription assays in situ and immunoﬂuorescence
Active transcription sites were labeled by the incorporation of 5′-
ﬂuorouridine (5′-FU) into nascent RNA, as previously reported [42].
Brieﬂy, under anesthesia both control and bortezomib-treated rats
(n = 3 per group) were given an intravenous injection of 5′-FU
(Sigma, UK) at doses of 5 μl/g of a stock solution of 0.4 M 5′-FU in 0.9%
saline. All animals were sacriﬁced after 1 h post-injection of the haloge-
nated nucleotide and ﬁxed by perfusion with 3.7% paraformaldehyde in
HPEM buffer (2× HPEM: Hepes, 60 mM; Pipes, 130 mM; EGTA, 20 mM;
andMgCl2 · 6H2O, 4 mM) containing 0.5% Triton X-100 for 10 min. The
sensory ganglia were removed, washed in HPEM buffer containing 0.5%
Triton X-100 for 10 min and cut into small fragments. Mechanical senso-
ry ganglia dissociation was performed as previously described. Then, the
samples were sequentially treated with proteinase K (2.5 μg/ml in 1 M
Tris buffer, pH 8) for 1 min at 25 °C, 0.1 M glycine in PBS containing
1% bovine serum albumin (BSA) for 15 min, and 0.01% Tween 20 in
PBS for 5 min. The incorporation of 5′-FU into nascent RNA was detec-
ted with a mouse monoclonal (clone BU-33) anti-BrdU antibody
(Sigma, UK) diluted 1:50 in PBS (overnight at 4 °C). The samples were
then washed with 0.05% Tween 20 in PBS, incubated for 45 min with
an anti-mouse FITC-conjugated secondary antibody (Jackson Laborato-
ries, West Grove, PA, USA), washed in PBS, and mounted with the Pro-
Long (Invitrogen).
2.7. Real time quantitative PCR (RTqPCR) for relative gene expression
analysis
Total RNA was extracted and cleaned from the two trigeminal gan-
glia using Trizol (TR-118, Molecular Research Center, Inc.) following
the manufacturer's instructions. Three animals per group were used.
RNA samples were quantiﬁed using a spectrophotometer (Nanodrop
Technologies ND-1000). First-strand cDNA was synthesized by RT-PCR
using a RevertAIT HMinus First Strand cDNA Synthesis kit (Thermo Sci-
entiﬁc). The cDNA concentrationwasmeasured in a spectrophotometer
(Nanodrop Technologies ND-1000) and adjusted to 0.3 mg/ml. qPCR
was performed using the Mx3005P system (Stratagene) with automa-
tion attachment. In this work, we have used SYBRGreen (Takara)
based qPCR. RpS14 was chosen as the normalizer in our experiments.
Expression level was evaluated relative to a calibrator according to the
2-(DDCt) equation. Mean values for fold changes were calculated for
each gene. The relative levels of 45S pre-rRNA and mature 18S rRNA
were calculated as previously reported [43]. Each value in thiswork rep-
resents the mean ± SEM of 3 independent samples obtained under the
same conditions. Data were analyzed using one-way ANOVA followed
by Bonferroni tests for comparisons. Statistical signiﬁcance was set at
p b 0.05. All the analyses were carried out using GraphPad software
for Windows. Primers used for qPCR are indicated in the Table 1.
2.8. Conventional and immunoelectron microscopy
For conventional ultrastructural examinationof sensoryneurons, con-
trol and bortezomib-treated rats (n = 2 per group)were perfused under
deep anesthesia with 1% paraformaldehyde and 1% glutaraldehyde in
0.1 M phosphate buffer, pH 7.4. DRG were removed, rinsed in 0.1 Mphosphate buffer, postﬁxed in 2% osmium tetroxide, dehydrated in ace-
tone and embedded in araldite (Durcupan, Fluka, Switzerland). Ultrathin
sections stainedwith uranyl acetate and lead citratewere examinedwith
a JEOL 201 electron microscope.
For immunoelectron microscopy of ﬁbrillarin and 5´-FU incorpora-
tion sites into nascent RNA, control and bortezomib-treated rats were
perfused with 3.7% paraformaldehyde in 0.1 M cacodylate buffer for
10-min at room temperature. In the case of 5′-FU incorporation, this
halogenated precursor was administrated as described above. Small
tissue fragments of trigeminal ganglia were washed in 0.1 M cacodylate
buffer, dehydrated in increasing concentrations of methanol at−20 °C,
embedded in Lowicryl K4 M at−20 °C and polymerized with ultravio-
let irradiation. Ultrathin sections were mounted on nickel grids and
sequentially incubated with 0.1 M glycine in PBS for 15 min, 5% BSA
in PBS for 30 min and the primary rabbit anti-ﬁbrillarin or mouse
monoclonal anti-BrdU antibody (diluted 1:25 in 50 mM Tris–HCl,
pH 7.6, containing 1% BSA and 0.1 M glycine) for 1 h at 37 °C. After
washing, the sections were incubated with the speciﬁc secondary anti-
bodies coupled to 15-nm gold particles (BioCell, UK; diluted 1:50 in PBS
containing 1% BSA). Following immunogold labeling, the grids were
stained with lead citrate and uranyl acetate and examined with a JEOL
201 electron microscope. As controls, ultrathin sections were treated
as described above but with the primary antibody being omitted.
2.9. SDS-PAGE and immunoblotting
Trigeminal ganglia from control and bortezomib-treated rats (n = 4
per group) were lysed at 4 °C in a buffer containing 20 mM Hepes
(pH 7.5), 10 mM EGTA, 40 mM b-glycerophosphate, 1% Nonidet P-40,
2.5 mM MgCl2, 1 mM dithiothreitol, 2 mM sodium vanadate, 1 mM
PMSF, 20 mg/ml aprotinin, 20 mg/ml leupeptin, and then cleared by
centrifugation at 14,000 rpm for 20 min at 4 °C. Proteins were separat-
ed on SDS–PAGE gels and transferred to nitrocellulose membranes by
standard procedures. Rabbit polyclonal anti-pP53 (Ser 15), anti-coilin
and anti-Myc, mouse monoclonal anti-p53 and goat anti-actin were
used. Protein bands were detected with an OdysseyTM Infrared-
Imaging System (Li-Cor Biosciences) according to OdysseyTM Western-
Blotting Protocol. Immunoblots were developed with anti-mouse and
anti-goat IRDye800DX or anti-rabbit IRDye700DX (Rockland Immuno-
chemicals, USA) secondary antibodies. For the quantitative analysis of
the blots we used ImageJ software (U. S. National Institutes of Health,
Bethesda, Maryland, USA, http://imagej.nih.gov/ij).
3. Results
3.1. Proteasome inhibition increases the size and number of nucleoli and
induces chromatolysis
The intravenous administration of Btz-LD (0.2 mg/kg) or Btz-HD
(0.5 mg/kg) was well tolerated by the Sprague–Dawley rats, and the
animals survived these treatment protocols. Bortezomib induced dose-
dependent changes in the nuclear and cytoplasmic organization of
sensory ganglion neurons. The cytochemical staining for nucleic acids
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control neurons. It was characterized by a prominent and rounded nucle-
olus, clearly demarcated from the pale euchromatic nucleus, and numer-
ous Nissl bodies throughout the cytoplasm (Fig. 1A). Upon bortezomib
treatment, the euchromatic conﬁguration of the nucleus was preserved,
but an apparent increase in the nucleolar size, accompanied by variable
levels of dissolution of Nissl bodies (chromatolysis) andnuclear eccentric-
ity, was observed (Fig. 1B, C). Electronmicroscopy analysis conﬁrmed the
dispersion of polyribosome aggregates and rough endoplasmic reticulum
cisterns in chromatolytic domains of the cytoplasm (Fig. 1D, E).Moreover,
there were no morphological signs of neuronal apoptosis or necrosis.
Themorphometric estimation of the nucleolar size and number was
performed in large neurons (≥40 μm) immunostained with B23, a
nucleolar marker. The nucleolar diameter of mononucleolated neurons
showed a signiﬁcant and dose-dependent increase in bortezomib-
treated neurons as compared with controls (Fig. 1F), reﬂecting anFig. 1. A–C. Representative confocal images of control (A) and bortezomib-treated (B,C) senso
typical distribution of cytoplasmic Nissl bodies and a round nucleus with a prominent nucleolu
hypertrophy. Scale bar: 5 μm. D and E. Electron microscopy of the typical organization of the
chromatolytic neuron (E). Scale bar: 1 μm. F. Morphometric analysis of the nucleolar diameter
hypertrophy. Data are mean ± SD from three independent experiments; *p b 0.01; **p b 0.00
six nucleoli showed a bortezomib-induced increase in multinucleolated neurons.augmentation of the nucleolar mass. As the whole cell nucleus could
be seen in dissociated neurons, it was possible to make an accurate
quantitative analysis of the number of nucleoli per cell. Whereas
66.05% of the control sensory ganglia neurons were mononucleolated,
this proportion signiﬁcantly dropped to 26.54% after treatment with
Btz-HD (Fig. 1G), resulting in a signiﬁcant increase in neurons with 2
to 4 nucleoli (Fig. 1G). These multinucleolated neurons exhibited
great variations in the size of nucleoli in a given neuron (Fig. 1G).
3.2. Bortezomib treatment preserves the reticulated nucleolar conﬁguration
of sensory ganglion neurons
Wenext investigated by electronmicroscopywhether proteasome in-
hibitionmodiﬁed the nucleolar architecture in sensory ganglion neurons.
Control neurons exhibited a rounded euchromatic nucleus with several
areas of interchromatin granule clusters and a prominent reticulatedry ganglion neurons stained with propidium iodide (PI). The control neuron exhibits the
s. Bortezomib treatment induces nuclear eccentricity, central chromatolysis and nucleolar
rough endoplasmic reticulum (RER) in a control neuron (D) and of its dissolution in a
in mononucleolated large neurons revealed that bortezomib-treatment induces nucleolar
1. G. Quantitative analysis of the percentage of neurons with one, two, three and four to
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clear euchromatic conﬁguration was preserved (Fig. 2B). Morphological
nuclear hallmarks of proteasome inhibitionwere the increase in the nu-
cleolar size and the formation of clusters of ring-shaped dense bodies
(Fig. 2B), which we have previously reported as poly(A) RNA granules
[39]. Some of these granules appeared closely associatedwith the nucle-
olar surface (Fig. 2B, inset).
In control sensory ganglia neurons, almost all nucleoli (93.4%; n = 3
animals; 50 nucleoli per animal) displayed the typical reticulated nucle-
oli of this neuronal population [38]. The ultrastructural features
included i) numerous small ﬁbrillar centers surrounded by a shell ofFig. 2. A and B. Representative electronmicrographs of nuclei from control (A) and bortezomib-tr
granule clusters (asterisks) and prominent nucleoli. Note the larger size of the nucleolus and the
inset). Scale bar = 1 μm. C–F. Electron micrographs of reticulated nucleoli from control (C) and
reticulated conﬁguration with numerous small FCs, surrounded by a shell of the DFC, and small m
conﬁguration, but of greater nucleolar size, is preserved following bortezomib treatment (D). Upo
the nuclear structure (F) associated with the presence of electron-dense microspherules (arrows)dense ﬁbrillar component, ii) reticulated strands of dense ﬁbrillar or
granular components, and iii) nucleolar interstices (Fig. 2C). The
granular component also formed small irregular masses intermingled
with the reticulated strands. After bortezomib treatment, the reticulated
nucleolar conﬁgurationwas preserved in themajority (84%with Btz-LD
and 81.4% with Btz-HD; n = 3 animals per condition; 50 nucleoli per
animal) of nucleoli (Fig. 2D). The remaining nucleoli exhibited moder-
ate nucleolar alterations. They included the accumulation of the granu-
lar component in several larger masses (Fig. 2E) or the appearance of
irregular-shaped reticulated nucleoli with microspherules of dense
ﬁbrillar material [44] trapped in the nucleolar interstices or locatedeated (B) neurons. Both neuronal nuclei exhibit a euchromatin pattern, small interchromatin
presence of clusters of ring-shaped nuclear bodies in the neuron exposed to Btz-HD (B and
bortezomib-treated (D–F) neurons. The nucleolus of control neuron (C) shows the typical
asses or strands of the GC. Note the presence of a nucleolus-attached CB. A similar reticulated
n proteasome inhibition a few neurons exhibit large masses of GC (E) or partial unraveling of
. Scale bar = 0.5 μm.
853A. Palanca et al. / Biochimica et Biophysica Acta 1842 (2014) 848–859at the nucleolar surface (Fig. 2F). However, the nucleolar macro-
segregation previously reported in sensory ganglion neurons after the
inhibition of RNA pol I transcription with actinomycin D [42,45] was
not observed upon proteasome inhibition.
3.3. Bortezomib treatment does not interfere with nucleolar transcription
Since previous studies in neurons and non-neuronal cells have
shown that the organization of FCs correlatewith the transcriptional ac-
tivity of the rDNA [14,26,16], we have analyzed whether proteasome
inhibition impacts on the organization of FCs. These structures concen-
trate components of the RNA pol I transcription machinery, including
the upstream binding factor (UBF), which is a reliable marker of FCs in
mammalian neurons [26,45]. With immunoﬂuorescence for the UBF,
FCs appeared as numerous small-size spots, ranging from 0.15 to
0.5 μm, distributed throughout the nucleolar body in both control and
bortezomib-treated neurons (Fig. 3A–C). Moreover, proteasome inhibi-
tion did not induce segregation of UBF at the nuclear periphery, as has
been reported after the inhibition of rRNA synthesis with actinomycin
D [45,46]. In conclusion, proteasome inhibitionpreserves the basic orga-
nization of FCs in sensory ganglion neurons.
We then proceeded to investigate whether proteasome inhibition
interfered with nucleolar transcription using an in situ run-on assay
based on the incorporation of the halogenated RNA precursor 5′-FU
into nascent RNA. The incorporation was visualized with an anti-BrdU
antibody. Following 1 h of the intraperitoneal injection of 5′-FU, the
nucleolus of control neurons appeared intensely labeled (Fig. 3D). The
labeling was not homogenous with nucleolar domains of higher 5′-FU
incorporation. In addition, numerous extranucleolar transcription foci
were observed (Fig. 3D). Interestingly, a strong nucleolar incorporation
of 5′-FU was also detected in all bortezomib-treated neurons, even in
the more affected neurons with elongated and eccentric nuclei
(Fig. 3E, F). Moreover, nucleoli frequently exhibited small rings of higher
5′-FU incorporation that presumably corresponded to the shell of DFC
around of FCs (Fig. 3E). Immunoelectron localization of 5′-FU incor-
poration sites conﬁrmed the nucleolar concentration of nascent pre-
rRNA in both control and bortezomib-treated neurons and revealed
the predominant distribution of immunogold particles on the DFC
(Fig. 4A–D). Small rings of DFC decorated with gold particles were fre-
quently found after bortezomib treatment (Fig. 4C). Moreover, some
masses of GC showed a moderate labeling indicating the migration of
newly synthesized pre-rRNA from the DFC to the GC, where the late
processing of this RNA occurs [14,15]. As a negative control, both Cajal
bodies, lacking inDNA [33], and the transcriptional silent heterochroma-
tin masses attached to the nucleolus appeared free of nascent RNA
(Fig. 4A).
To further understand the transcriptional behavior of neuronal
nucleoli upon proteasome inhibition, we performed immunostaining
for the chaperone B23, a nucleolar protein with a transcription-
dependent expressionpattern inmammalianneurons [47,28]. In control
neurons, B23 was predominantly nucleolar, with a non-homogenous
staining reﬂecting its distribution in the granular component [15,16].
In addition, a weak diffuse nucleoplasmic staining for B23was observed
(Fig. 3G). A similar nucleolar and nucleoplasmic staining pattern was
observed in bortezomib-treated neurons, which displayed hypertrophic
and intensely labeled nucleoli with the anti-B23 antibody (Fig. 3H, I).
Disruption of nucleolar staining or nucleoplasmic accumulation of
B23, two cellular events associated with inhibition of nucleolar tran-
scription [47,30,19], were not observed. These ﬁndings are consistent
with the in situ transcription assay showing a high nucleolar transcrip-
tion upon proteasome inhibition.
Because proteasome inhibitors induce nucleolar aggregation of
proteasome substrates and polyadenylated RNA in cultured ﬁbro-
blasts [22], we analyzed the possible association of poly(A) granules
of bortezomib-treated neurons with the nucleolus. In situ hybridization
for poly(A) RNAs revealed their concentration in nuclear specklesand cytoplasmic Nissl bodies, as previously reported [26,39], and their
absence in the nucleolus (Fig. 3J). Proteasome inhibition induced
a dose-dependent formation of nuclear poly(A) granules, some of
them localized at the nucleolar surface, but not within the nucleolus
(Fig. 3K, L). This was accompanied by different levels of poly(A) RNA
loss in nuclear speckles and Nissl bodies (Fig. 3K, L). Furthermore,
immunogold electron microscopy localization of 5′-FU incorporation
sites demonstrated the absence of recently synthesized RNA in the
poly(A) granules associated with the nucleolus, reﬂecting that they are
not transcription sites (Fig. 4D).
3.4. Bortezomib treatment increases the levels of both 45S rRNA andmRNAs
encoding some proteins involved in rRNA synthesis and processing
To further support the possibility that bortezomib treatment in-
creases transcription mediated by RNA pol I in sensory ganglia, we
determined by quantitative RT-PCR the levels of 45S pre-rRNA and
mature 18S rRNA. The 45S precursor is very short lived and is consid-
ered as an indicator of RNA-pol-I activity [48]. Bortezomib treatment
signiﬁcantly increased both 45S pre-rRNA and 18S rRNA levels in
sensory ganglia as compared to controls (Table 2). This ﬁnding sup-
ports the notion that the inhibition of proteasome induces a com-
pensatory response to the proteotoxic stress partially mediated by
the activation of nucleolar transcription. In agreement with this
view, we have detected a dose-dependent increase in the expression
of mRNA transcripts encoding the UBF transcription factor of the
RNA pol I (Table 2). Similarly, the genes encoding ﬁbrillarin and
B23, two key proteins for pre-rRNA processing and assembly of
preribosomal particles [14,15], were up-regulated (Table 2). Howev-
er, no signiﬁcant changes in the mRNA levels of nucleolin were de-
tected upon proteasome inhibition.
To further understand the transcriptional response of the neuronal
nucleolus to proteasome inhibition, we analyzed the expression levels
of two regulators of RNA pol I transcription, the oncoprotein c-Myc
and the tumor suppressor p53. c-Myc is a major cell growth regulator
that stimulates ribosome biogenesis [49,50]. Interestingly, mRNA and
protein levels of c-Myc showed a signiﬁcant and dose-dependent
increase in sensory ganglia of bortezomib-treated rats as compared
with control ganglia (Table 2; Fig. 6). The transcription factor p53
is an important transducer of the cellular stress response and can
function as an inhibitor of RNA pol I transcription [51]. Unlike c-
Myc, the expression levels of the mRNA encoding p53 signiﬁcantly
decreased in sensory ganglia of bortezomib-treated rats as compared
to controls. Moreover, Western blot analysis of protein levels of both
the phosphorylated (Ser 15) and total forms of p53 revealed the
absence of p53 activation in sensory ganglia upon bortezomib treat-
ment (Table 2, Fig. 6).
3.5. Bortezomib treatment increased Cajal body number in sensory
ganglion neurons
Since CBs are involved in the biogenesis pathway of snoRNAs
required for pre-rRNA processing [52,36], we investigated whether
the bortezomib-induced increase in both the nucleolar mass and rRNA
biosynthesis affects the organization and assembly of CBs. Double
immunolabeling for coilin and SMN revealed the presence of typical
CBs immunolabeled for these two CB markers in both untreated and
bortezomib-treated neurons (Fig. 5A–C). They appeared free in the
nucleoplasm or attached to the nucleolus. Moreover, the diffuse cyto-
plasmic staining of SMN was preserved upon bortezomib treatment.
The quantitative analysis of the mean number of CBs per neuron on
whole dissociated neurons immunostained for coilin and SMN showed
a dose-dependent signiﬁcant increase in CBs upon proteasome inhibi-
tion (Fig. 5I). It is also noteworthy that coilin did not relocalize within
the nucleolus following bortezomib treatment, as occurs under certain
Fig. 3. A–C. Immunostaining for theUBF illustrates the organization of FCs in control (A) and bortezomib-treated (B and C) neurons. FCs in all neurons appeared as numerous UBF-positive
spots of variable size distributed throughout the nucleoli body. D–F. Representative examples of in situ transcription assayswith 5′-FU incorporation in control (D) and bortezomib-treated
neurons (E and F) 1 h post-injection of the halogenated nucleotide. In addition to the labeled nucleolus, numerous transcription foci of 5′-FU incorporation were detected throughout the
nucleus. Note the strong nucleolar incorporation of 5′-FU into nascent RNA upon proteasome inhibition (E and F) and the formation of ring-shaped nucleolar domains of highest 5′-FU
incorporation (E) identiﬁed as the DFC around of FCs. G-I. B23 immunostaining of control (G) and bortezomib-treated (H and I) neurons. In all neurons, B23 appear concentrated in
the nucleolus and only a weak diffuse nucleoplasmic staining is observed. Note in H the coexistence of an hypertrophic nucleolus and a micronucleoli. Scale bar, A-I = 5 μm. J–L. In
situ hybridization for poly(A) RNA in control (J) and bortezomib-treated (K and L) neurons. In the control neuron (J) poly(A) RNAs concentrate in nuclear speckles and in cytoplasmic
Nissl bodies, but are absent from the nucleolus. After bortezomib treatment polyadenylated RNAs accumulate in nuclear poly(A) RNA granules, whereas the hybridization signal tends
to disappear from Nissl bodies and nuclear speckles in parallel with the progression of the chromatolysis (K and L). Scale bar = 10 μm.
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transcription [53–55].
The abundance of CBs following bortezomib treatment and their
association with the nucleolus was also conﬁrmed in co-staining exper-
iments for ﬁbrillarin, a snoRNP-associated nucleolar protein sharedwithCBs [56,34,35], and coilin (Fig. 5D–F). Immunoelectron localization of
ﬁbrillarin revealed that almost all CBs in bortezomib-treated neurons
exhibited the typical morphology of coiled threads of dense ﬁbrillar
material which appeared immunolabeled for ﬁbrillarin (Fig. 4G), as
previously reported in control sensory ganglion neurons [38]. However,
Fig. 4. A–C. Immunogold electron microscopy localization of the newly synthesized RNA in nucleoli of control (A) and bortezomib-treated (B–D) neurons. Al nucleoli appear intensely
decorated with gold particles of 5′-FU incorporation. Note the absence of 5′-FU labeling in CBs and in a nucleolus-attached heterochromatin mass (arrow in A). In all cases, most
immunogold particles predominantly decorated the reticulated strands of DFC. Note in the panel D the absence of nascent RNA in a poly(A) granule located at the nucleolar surface
(arrow). Scale bar, A–C = 1 μm, D = 0.4 μm.
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segregated with a mass of dense ﬁbrillar material immunoreactive for
ﬁbrillarin separated from the coiled threads (Fig. 5H).
Given that coilin has an essential role in the assembly and integrity
of CBs [56–58], we analyzed the changes in mRNA and protein levels
induced by proteasome inhibition in sensory ganglia. Whereas coilin
mRNA signiﬁcantly increases upon bortezomib treatment (Table 2),
no signiﬁcant variations were detected in protein levels as compared
with control samples (Fig. 6).Table 2
Effects of bortezomib treatment on the relative amounts of speciﬁc transcripts related to
nucleolar and CB biology.
Name Control Btz-LD Btz-HD
Fbl 1 1.30 ± 0.015⁎⁎ 1.91 ± 0.06⁎⁎⁎⁎
Nucleophosmin 1 1.04 ± 0.06 1.50 ± 0.08⁎⁎⁎
Ubtf 1 1.41 ± 0.09⁎⁎ 2.20 ± 0.16⁎⁎⁎⁎
Nucleolin 1 1.08 ± 0.05 1.11 ± 0.05
Tp53 1 0.43 ± 0.015⁎⁎⁎ 0.43 ± 0.04⁎⁎⁎
c-myc 1 1.36 ± 0.05⁎⁎ 2.39 ± 0.14⁎⁎⁎⁎
Coilin 1 1.17 ± 0.05⁎ 1.35 ± 0.08⁎⁎
45S pre-rRNA 1 1.59 + 0.10⁎⁎⁎ 2.49 ± 0.10⁎⁎⁎⁎
18S rRNA 1 1.49 ± 0.10⁎⁎⁎ 2.37 ± 0.19⁎⁎⁎⁎
Values are expressed as fold changes versus control samples and given as mean ± SEM.
⁎ p-value b 0.05.
⁎⁎ p-value b 0.01.
⁎⁎⁎ p-value b 0.001.
⁎⁎⁎⁎ p-value b 0.0001 when compared to control.4. Discussion
The present study demonstrates that treatments with low doses of
bortezomib (0.2 mg/kg), similar to the dose used for the treatment
of multiple myeloma, or higher doses (0.5 mg/kg) induce a dose-
dependent reactive response in nucleoli and related CBs of sensory
ganglion neurons. This response is characterized by an increase in the
number and size of nucleoli, up-regulation and pre-rRNA synthesis
and enhanced CB assembly.
Bortezomib has been shown to be an effective anticancer drug, but
the sensory peripheral neuropathy represents the dose-limiting side
effect of treatment [9,12]. Several studies in animal models have
shown that sensory ganglion neurons, together with Schwann and
satellite glial cells, are cellular targets of bortezomib neurotoxicity
[39,40,59]. In a rat model, we have previously reported that chronic
administration of Btz-LD produces chromatolysis and nuclear retention
of poly(A) RNA granules, suggesting a dysfunction of protein synthesis
and pre-mRNAprocessing [39].More severe alterations consisting of con-
densation of some neuronal bodies, partial segregation of nucleolar com-
ponents and degeneration of satellite glial cells have been reported in a
mousemodel upon treatmentwithhigh doses (0.8 mg/kg) of bortezomib
[40]. Taken together, these data support that the dysfunction of sensory
ganglion neurons appears to be an essential component in the patho-
physiology of the bortezomib-induced peripheral neuropathy.
Commonly, the sensory peripheral neuropathy reverses after
bortezomib dose reduction or discontinuation [9,12], suggesting
that proteasome inhibition induces a survival response in sensory
ganglion neurons to counteract proteotoxic stress and to prevent
Fig. 5. A–C. Confocalmicroscopy images representative of control (A) and bortezomib-treated (B–Z) neurons double immunolabeled for coilin and SMN. In all neurons coilin colocalizeswith
SMN in CBs. Note the diffuse cytoplasmic staining of the SMN and the abundance of CBs in the bortezomib-treated neuron with an eccentric nucleus (C). Scale bar = 5 μm. D–F. Double
immunostaining for coilin and ﬁbrillarin in a bortezomib-treated neuron. Note the nucleolar concentration of ﬁbrillarin and its colocalization with coilin in numerous nucleolus-attached
CBs. Scale bar = 2 μm.G andH. Immunogold electronmicroscopy localization ofﬁbrillarin in twoCBs of bortezomib-treated neurons.Whereas one typical CB shows thedense coiled threads
decoratedwith immunogold particles (G) the other CB (H) appears segregatedwith a densemass decoratedwith numerousgoldparticles. Scale bar = 0.15 μm. I.Quantitative analysis of the
average number of CBs per nucleus in control and bortezomib-treated large neurons. Proteasome inhibition induces a signiﬁcant increase in the number of CBs. Data are mean ± SD from
three independent experiments; **p b 0.001.
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absence of degenerating neurons and the induction of nucleolar chang-
es that includes an increase in the number and size of nucleoli, and ac-
tivation of nucleolar transcription. Nucleolar hypertrophy and
activation of rRNA synthesis appear to reﬂect a neuronal compensatory
reaction to the dysfunction of protein synthesis machinery (chromatol-
ysis) induced by proteasome inhibition.
Bortezomib-induced increases in nucleoli number suggests the acti-
vation of a mechanism of nucleologenesis. It is well known that the
theoretical maximum number of nucleoli is determined by the number
of chromosomes carrying nucleolar organizers regions (NORs). These
regions contain tandem repetitions of rRNA genes and each of which
may potentially organize the formation of a nucleolus [60,14,16]. Rat
sensory ganglia neurons are diploid cells that have six NORs, resulting
in a theoretical maximum number of six nucleoli per neuron [38]. The
predominance of a single nucleolus reported here and previously in
large control neurons [38] may result from the spatial association of
NORs and fusion of nucleoli during differentiation as well as from the
existence of some inactive NORs that do not contribute to the formationof nucleoli [23,60]. In this context, the bortezomib-induced increase in
nucleoli number may reﬂect the activation of transcriptional repressed
NORs resulting in the assembly of additional nucleoli required to
enhance ribosome biogenesis. Consistent with this, a recent study has
shown that prolonged neuronal stimulation induces an increase in
nucleolar number and protein synthesis, suggesting the activation of
nucleologenesis [27].
Nucleolar size is a parameter related to nucleolar transcription that
reﬂects the rate of pre-rRNA synthesis and processing to produce
preribosomal particles [14,16]. As such, in human sensory ganglia
neurons and in a ratmodel of osmotic stimulation of supraoptic neurons
we have previously observed a direct relationship between the nucleo-
lar size and both neuronal body size and transcriptional activity [24,26].
In this context, we propose that the increase in nucleolar size induced
by proteasome inhibition clearly correlates with the activation of nucle-
olar transcription and represents another indicator of the nucleolar
reactive response to the proteotoxic stress. The preserved reticulated
morphology of nucleoli and their active incorporation of 5′-FU in
bortezomib-treated neurons reasonably rule out the possibility that
Fig. 6.Western blotting of trigeminal ganglia lysates shows the absence of p-53 activation
upon proteasome inhibition. A dose-dependent increase of c-Myc protein levels was
detected upon bortezomib treatment, whereas no variations in coilin levels were observed.
Quantiﬁcation of protein levels were normalized to actin, and the fold increase estimated.
Representative blots of three independent experiments.
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proteasome targets. Variations of the nucleolar size have been related
to aging and neurodegenerative disorders [61,28,62]. For instance,
whereas reduced nucleolar volume indicative of the silencing of ribo-
somal genes has been reported in neuronal populations affected by
Alzheimer's disease, a compensatory nucleolar hypertrophy occurs in
cortical and hippocampal neurons from asymptomatic patients with
this disease [63,64,28]. As occurs in bortezomib-treated neurons, nucle-
ar eccentricity, severe chromatolysis, nucleolar hypertrophy and
increased rRNA levels are cellular hallmarks of the stress response to
axotomy in sensory ganglion neurons and other peripheral neurons
[25,65,66]. Interestingly, the nucleolar response to axotomy has been
considered as a reparative mechanism, which is essential for a success-
ful regeneration of axotomized neurons [25].
It is well established that the nucleolus senses cellular stress and
coordinates the stress response [17,18]. In fact, a dramatic structural
and molecular reorganization of nucleoli has been previously reported
in response to different types of cellular stress. Notably, most cellular
stresses that generate nucleolar alterations, such as segregation of the
DFC and GC, formation of perinucleolar caps of the UBF or translocation
to the nucleoplasm of B23, are p53-dependent and are accompanied by
transcriptional inhibition of the RNA pol I [18,29,67]. Different
factors have been reported to trigger this inhibition, including treat-
mentswith genotoxic agents or transcriptional inhibitors and the condi-
tional ablation of the transcription initiation factor TIF-IA in mice
[29,47,62,68,69]. Interestingly, the proteotoxic stress in sensory gangli-
on neurons preserves the normal structural organization of the neuro-
nal nucleolus and enhances 45S rRNA synthesis. However, it does not
seem to require the activation of p53. This is consistent with the recent
demonstration that bortezomib treatment reduces p53 expression in an
animal model of retinal ischemia-reperfusion injury [70]. Moreover, we
have previously reported in sensory ganglion neurons a transient
activation of p53 upon ionizing radiation treatment (4 Gy). In this ex-
perimental model, the increase in p53 expression is associated with adrop in nucleolar transcription, suggesting a negative relationship be-
tween the activation of p53 and transcriptional activity of the nucleolus
[71].
Recent studies in cultured cell lines indicate that cells can compen-
sate for an impairment of proteasome activity by transcriptional activa-
tion of antioxidant defense genes including all 26S proteasome subunit
genes [72]. Our results in sensory ganglion neurons show that protea-
some inhibition upregulates genes encoding UBF, ﬁbrillarin and B23,
which are essential proteins for pre-rRNA synthesis and processing
[14–16]. Furthermore, the bortezomib-induced increase in the expres-
sion of c-Myc, a positive regulator of ribosome biogenesis [49,50], may
simply result from inhibition of its degradation by the proteasome. How-
ever, the parallel signiﬁcant increase in the mRNA expression of c-myc
raises the possibility that c-Myc could be involved in the nucleolar
response to proteotoxic stress. In this context, our results suggest that
the nucleolar reaction could represent a protective mechanism to com-
pensate the dysfunction of protein synthesis machinery caused by the
partial dissolution of the Nissl bodies. In human cultured cell lines, how-
ever, it has been shown that short proteasome inhibition treatments
alter the nucleolar morphology and interfere with pre-rRNA processing
[21]. The discrepancy with our results may result from the different
experimental protocols for treatments with proteasome inhibitors; we
use a prolonged treatment for 4 days on whole animals, and from a dif-
ferent neuronal response to proteasome inhibition.
Regarding the increase in CB number following bortezomib treat-
ment, we propose that it reﬂects the coordination of CB assembly with
nucleolar pre-rRNA processing. A reactive bortezomib-induced activa-
tion of CB assembly is also suggested by the increased expression levels
of coilin mRNA. Indeed, coilin is an essential regulator of CB assembly
[56–58]. Moreover, CBs in bortezomib-treated neurons preserve the
structural and molecular organization of canonical CBs [33,34,36], sug-
gesting that they are actively engaged in the biogenesis of snRNP and
snoRNP required for pre-mRNAand pre-rRNA processing. The occasion-
al presence in bortezomib-treated neurons of a partially segregated CB
is a morphological variant, which has also been found in normal gangli-
on neurons [38]. Our results are also consistent with the view that CBs
are transcription-dependent nuclear structures whose formation ac-
commodates the nuclear demand of RNA processing [24,37,33,34,27].
In fact, most stress signals that cause CB disruption are associated with
transcription inhibition [69,18,53]. Consistentwith this,we have recent-
ly reported disruption of CBs accompanied by nucleolar segregation in a
mouse model of Purkinje cell degeneration in which the accumulation
of DNA damage causes transcription inhibition [30].
The physical relationship between CBs and nucleoli observed in
bortezomib-treated neurons is a common ﬁnding in neuronal popula-
tions [56,32,38] and clearly reﬂects the functional link between these
two structures [33,27,54]. In support of this view, several proteins and
snoRNPs localize to both CBs and nucleoli [54] and certain snoRNPs un-
dergo biogenesis steps in CBs before their transfer to the nucleolus
where they are necessary for pre-rRNAprocessing [34,52]. Furthermore,
recent ﬁndings demonstrate that the nucleolar stress response also
involves the CB as a key target of signaling pathways triggered by a
variety of cellular insults [18]. In the case of the proteotoxic stress in-
duced by proteasome inhibition, the crosstalk between CBs and nucleoli
may facilitate ribosome biogenesis under conditions of severe neuronal
dysfunction.
In conclusion, the coordinated neuronal response of nucleoli and CBs
to the proteotoxic stress suggests a protective role, which may be
important for neuronal survival.Disclosure
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